Faculty

• Joseph Alvarnas, MD, City of Hope
• Francisco Arabia, Sr., MD, Banner Health
• Matthew Cooper, MD, Medical College of Wisconsin
• Vanessa Ann Fabrizio, MD, MS, Children’s Hospital Colorado
• Kelly Grosklags, LICSW, BCD, FAAGC, FT, Conversations with Kelly
• Irene K. Kim, MD, FACS, Cedars-Sinai Medical Center
• Bonnie E. Lonze, MD, PhD, NYU Langone Transplant Institute
• Philip Mack, PhD, Mount Sinai Health System
• Navneet Majhail, MD, MS, FASTCT, Sarah Cannon Cancer Institute
• Amit K. Mathur, MD, MS, FACS, Mayo Clinic
• David F. Mercer, MD, PhD, FRCS (C), FACS, University of Nebraska Medical Center
• Javier L. Munoz, MD, MBA, Mayo Clinic in Arizona
• Satish Nadig, MD, PhD, FACS, Northwestern Medicine
• Marie Neumann, MA, University of Nebraska Medical Center
• Bryan Piatt, Mental Health Advocate
• Mark Stegall, MD, Mayo Clinic

Planners

Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Matthew Cooper, MD
Mark B. Adams Chair in Transplant Surgery
Chief, Division of Transplant Surgery
Director, Solid Organ Transplant Service Line
Froedtert Memorial Lutheran Hospital;
Director, Solid Organ Transplantation
Children’s Wisconsin;
Tenured Professor of Surgery
Medical College of Wisconsin

Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education

Katie L. Lo Coco RN, BSN, CCTC, CCM
Clinical Operations Manager for Transplant Solutions M&R
Optum Health

C. Fred LeMaistre, MD
Senior Vice President
Senior Vice President, Market Operations
Physician-in-Chief, Hematology
Sarah Cannon

Navneet Majhail, MD, MS, FASTCT
Physician-in-Chief of Blood Cancers
Director, Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial
Sarah Cannon Cancer Institute

Tina Rydland, PharmD
Executive Pharmacy Consultant

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Financial Relationship Key
 A-Advisory Board
 CT-Clinical Trial
 C-Consultant
 E-Employee
 G- Grant/Research Support or Funding
 I-Stocks and Other Ownership Interests 
 S-Speakers’ Bureau
 O-Other Financial or Material Support

 Francisco Arabia, Sr., SynCardia Systems (C)

Vanessa Fabrizio: Adaptimmune (C)

Irene Kim: CareDx (C); Sanofi (A)

Bonnie Lonze: AlloVir, Inc, AbbVie, CareDx, Hansa Biopharma (G); ArgenX (A)

Philip Mack: Amgen, Vivace Therapeutics (C) 

Navneet Majhail: Anthem Inc (C); HCA Healthcare (I)    

David Mercer: Takeda, VectiveBio (G); Zealand Pharma (A, G)

Javier Munoz: Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly (C); Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene (G); Targeted Oncology, OncView, Curio, Physicians' Education Resource, and Seattle Genetics (S)

Satish Nadig: Pandorum Technologies (G, I)

Marie Neumann: Zealand Pharma (G); VectiveBio, Ironwood Pharmaceuticals (C, S)     

Mark Stegall: Aiosyn (C); Janssen, Transplant Genomics Inc; Veloxis (G)    

All relevant financial relationships have been mitigated. 

The remaining faculty and planners have no financial relationships to disclose.